10 nuovi farmaci in commercio

Nuove specialitÓ medicinali: Dupixent, Kanjinti, Solvetta. 7 nuovi farmaci equivalenti

Nuove specialità medicinali
DUPIXENT 2 siringhe 300 mg 2 ml dupilumab
SANOFI AIC:045676069 2112,51€ H/RNRL in commercio dal:22/10/2018

KANJINTI 1 flaconcino EV 150 mg trastuzumab
AMGEN AIC:046547016 763,10€ H/RNRL in commercio dal:21/09/2018

SOLVETTA 1 dispositivo vaginale 0,12 mg + 0,015 mg /24 h etonogestrel/etinilestradiolo
SANDOZ AIC:045048016 15,95€ Cnn/RR in commercio dal:24/09/2018

Nuovi farmaci equivalenti
ANAGRELIDE MYLAN 100cps 0,5mg fl anagrelide cloridrato
MYLAN SpA AIC:046101010 341,34€ A/RNRL in commercio dal:20/09/2018

CLOFARABINA TILLOMED 4fl 1mg/ml clofarabina
TILLOMED ITALIA Srl AIC:045349026 8403,84€ Cnn/OSP in commercio dal:18/09/2018

ENALAPRIL MYLAN GENERICS 28cpr 20mg enalapril maleato
MYLAN SpA AIC:036488500 4,87€ A/RR in commercio dal:20/09/2018

ENTECAVIR KABI 30cpr riv 0,5mg entecavir monoidrato
FRESENIUS KABI ITALIA SpA AIC:044996015 261,41€ A/RNRL in commercio dal:01/10/2018

ENTECAVIR KABI 30cpr riv 1mg entecavir monoidrato
FRESENIUS KABI ITALIA SpA AIC:044996041 261,41€ A/RNRL in commercio dal:01/10/2018

NEVIRAPINA ACCORD 30cpr 400mg rp nevirapina
ACCORD HEALTHCARE ITALIA Srl AIC:044335014 107,25€ H/RNRL in commercio dal:24/09/2018

PANTOPRAZOLO ABC 28cpr 40mg pantoprazolo sodico sesquidrato
ABC FARMACEUTICI SpA AIC:041022031 10,94€ A/RR in commercio dal:24/09/2018